Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

2.26USD
23 Sep 2016
Change (% chg)

$0.11 (+5.12%)
Prev Close
$2.15
Open
$2.25
Day's High
$2.41
Day's Low
$2.17
Volume
70,923,620
Avg. Vol
11,729,796
52-wk High
$9.88
52-wk Low
$1.16

Select another date:

Thu, Sep 15 2016

Novavax vaccine for respiratory disease fails in late stage trial

Novavax Inc said on Thursday that its experimental vaccine for a serious infectious respiratory disease failed at the final stage of human testing, sending its stock plunging more than 80 percent.

BRIEF-Novavax Q2 loss per share $0.29

* Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S

BRIEF-FDA grants fast track designation to Novavax' RSV F vaccine

* U.S. FDA grants fast track designation to Novavax' RSV F vaccine for older adults Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Novavax Inc Q1 loss per share $0.29

* Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Novavax reports Q1 loss per share of $0.29

* Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Select another date: